Back to search results
NCT06113315

A Study Involving Collection of Samples and Data From Sarcoma Patients Receiving Immunotherapy

Enrolling by Invitation
Not specifiedAll AgesObservational
Memorial Sloan Kettering Cancer Center
~250 participants
Updated 2025-10-27 on ClinicalTrials.gov

At a glance

Recruiting sites
0 of 7 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
prospectively collect and store blood
Measured over up to 5 years

Conditions

Sarcoma

Explore related trials

Sarcoma

Where it's being run

7 sites across 2 states
New York4
New Jersey3

Study leadership

  • Sandra D'Angelo, MD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Participants must have a histologic diagnosis of sarcoma confirmed by an MSK pathologist.
Any prospectively identified patient being treated or to be treated with an immune checkpoint inhibitor, such as anti-PD-1, anti-PD-L1, anti-CTLA-4, or anti-LAG3 inhibitor, either as monotherapy or in combination with additional systemic therapy OR any prospectively identified patient being treated or to be treated with ACT-based treatment including but not limited to lifileucil, Afamitresgene autoleucel, and letetresgene autoleuce o Novel immune checkpoints inhibitors that are developed after submission of this protocol will also be included) Please Note: there is no age requirement. Patients of all ages are eligible to enroll

Exclusion

Patient unwilling to consent to collection of historical and longitudinal clinicopathologic data in the patient medical record from baseline (the period prior to ICB or ACT initiation), during, and after ICB or ACT treatment

What this trial measures

  • prospectively collect and store bloodup to 5 years

    of sarcoma patients treated with ICB or ACT